Sacha Gnjatic, PhD
- ASSOCIATE PROFESSOR | Medicine, Hematology and Medical Oncology
- ASSOCIATE PROFESSOR | Oncological Sciences
- ASSOCIATE PROFESSOR | Pathology, Molecular and Cell Based Medicine
Research Topics:
Anti-Tumor Therapy, Antigen Presentation, B Cells, Cancer, Cellular Immunity, Dendritic Cells, Immunological Tolerance, Immunology, Immunosuppression, Lung, Microarray, Proteomics, T Cells, Tolerance, Translation, Vaccine Development Dr. Sacha Gnjatic received his PhD in Immunology
from the University of Paris VII after completing a fellowship at the Institut
Cochin in Paris. Following a post-doctoral fellowship in Lloyd J. Old’s
laboratory at Memorial Sloan-Kettering (MSKCC) in New York, Dr. Gnjatic
was appointed to the Ludwig Institute for Cancer
Research
at
MSKCC, where he eventually became Associate Member, and was named Director of
Immunological Monitoring at the Ludwig Center for Immunotherapy.
In 2013, Dr. Gnjatic moved to Icahn School of
Medicine at Mount Sinai, New York, where he was appointed as Associate
Professor of Medicine at the Tisch Cancer Institute and Immunology Institute.
In addition, he serves as Associate Director of the Human Immune
Monitoring Center at Mount Sinai.
Dr. Gnjatic focuses on human immune responses to
cancer in an antigen-specific manner, to define new targets for the development
of cancer immunotherapies, ask how these immunotherapies work and why they may
fail. Areas of research include: Characterization of serological and
cellular immune responses against tumor antigens such as MAGE-A3 or NY-ESO-1, spontaneously
occurring or induced by cancer immunotherapy, using state-of-the-art T cell
methods and large-scale seromic profiling; Mechanisms of antigen
presentation to T cells, to evaluate viral, bacterial, and parasitic vectors,
and cross-presentation of antigen to HLA; Impact of immunoregulation on tumor
antigen-specific responses, from co-inhibitory molecules expressed on T
cells at the tumor site to the effect of regulatory T cells and immune
checkpoint blockade on anti-tumor effectors, with a recent emphasis on the role
of immunosuppressive mechanisms in the tumor microenvironment.
Dr. Gnjatic’s research has established the
immunological bases for evaluating human cancer vaccines in over 40 clinical
trials. His work has resulted in more than 120 publications in high-impact
peer-reviewed journals and nearly 10 patents.
Multi-Disciplinary Training Area
Immunology [IMM]Education
BSc3, University College London
MSc, Institut Pasteur
Undergraduate, Ecole Normale Supérieure
PhD, University Paris VII
Memorial Sloan-Kettering - Ludwig Institute
Impact of immunoregulation on tumor antigen-specific responses:
Impact of immunoregulation on tumor antigen-specific responses, from co-inhibitory molecules expressed on T cells at the tumor site to the effect of regulatory T cells on anti-tumor effectors.
Mechanisms of antigen presentation to T cells:
Mechanisms of antigen presentation to T cells, including defining epitopes, evaluating viral, bacterial, and parasitic vectors, cross-presentation of antigen to HLA class I, and endogenous antigen presentation to HLA class II.
Characterization of serological and cellular immune responses against tumor antigens:
Characterization of serological and cellular immune responses against tumor antigens such as p53, MAGE-A3, and NY-ESO-1, for their capacity to induce immune responses both spontaneously and in the setting of cancer immunotherapy. Pioneering large-scale seromic profiling to find biomarkers and new targets of tumor immunity.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Gnjatic during 2021 and/or 2022. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Other Activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership.
- Bristol-Myers Squibb; Cancer Immunotherapy Trials Network (CITN); Celgene Corporation; Center for Cancer Immunology Research (CCIR); Frontiers in Immunology; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; National Cancer Institute (NCI); Regeneron Pharmaceuticals; Society of Immunotherapy of Cancer (SITC); Takeda Pharmaceutical Company Limited
Royalty Payments:
- GlaxoSmithKline
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.